Blood cancer (AML leukaemia)
Can Vildagliptin help reduce cancer stem cells in patients with blood cancer
Who can joinAdults
Age18+ years
Kind of studyPhase 2: does it work?
What it testsSee the registry
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
AIIMS RISHIKESHRishikeshDirections ↗
Registry summary (technical)
Comparison of Dasatinib plus DPP IV inhibitor Vildagliptin versus Dasatinib monotherapy in reduction of peripheral blood leukemic stem cells in chronic myeloid leukemia: a randomized, exploratory pilot study
Sponsor: DR ESWER SUBBAIYAN I
CTRI/2026/06/112499 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 3 Aug 2026 · read by us 5 Nov 2026